Figure S1 from A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors

Figure S1. Correlative Angiogenesis Biomarkers. A, levels of circulating endothelial cells in patients in schedule A and B at baseline (Pre-treatment). B, circulating endothelial precursor cells (EPCs) at baseline in patients in schedule A and B. C, baseline plasma angiogenic activity (PAA) at baseline in patients in schedule A and B.